BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 26369563)

  • 1. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
    Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
    Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial.
    Dahl R; Calverley PM; Anzueto A; Metzdorf N; Fowler A; Mueller A; Wise R; Dusser D
    BMJ Open; 2015 Dec; 5(12):e009015. PubMed ID: 26715479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tiotropium Respimat inhaler and the risk of death in COPD.
    Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P;
    N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
    ZuWallack R; Allen L; Hernandez G; Ting N; Abrahams R
    Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair
    Yildiz P; Bayraktaroglu M; Gorgun D; Secik F
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2859-2867. PubMed ID: 27920513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR
    Wise RA; Calverley PM; Carter K; Clerisme-Beaty E; Metzdorf N; Anzueto A
    Int J Chron Obstruct Pulmon Dis; 2018; 13():605-616. PubMed ID: 29497289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.
    Halpin DM; Dahl R; Hallmann C; Mueller A; Tashkin D
    Int J Chron Obstruct Pulmon Dis; 2015; 10():239-59. PubMed ID: 25709423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial.
    Wise R; Calverley PM; Dahl R; Dusser D; Metzdorf N; Müller A; Fowler A; Anzueto A
    NPJ Prim Care Respir Med; 2015 Nov; 25():15067. PubMed ID: 26540491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials.
    Calverley PM; Könen-Bergmann M; Richard F; Bell S; Hohlfeld JM
    Adv Ther; 2016 May; 33(5):786-93. PubMed ID: 27084728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIOtropium Safety and Performance In Respimat
    Zhong N; Moon HS; Lee KH; Mahayiddin AA; Boonsawat W; Isidro MG; Bai C; Mueller A; Metzdorf N; Anzueto A
    Respirology; 2016 Nov; 21(8):1397-1403. PubMed ID: 27490162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
    Ichinose M; Taniguchi H; Takizawa A; Grönke L; Loaiza L; Voß F; Zhao Y; Fukuchi Y
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2017-27. PubMed ID: 27621608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV
    Calverley PMA; Mueller A; Fowler A; Metzdorf N; Wise RA
    Ann Am Thorac Soc; 2018 Feb; 15(2):200-208. PubMed ID: 28957643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices.
    Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N
    J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale.
    Wise RA; Anzueto A; Calverley P; Dahl R; Dusser D; Pledger G; Koenen-Bergmann M; Joseph E; Cotton D; Disse B
    Respir Res; 2013 Apr; 14(1):40. PubMed ID: 23547660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch.
    Hanada S; Wada S; Ohno T; Sawaguchi H; Muraki M; Tohda Y
    Int J Chron Obstruct Pulmon Dis; 2015; 10():69-77. PubMed ID: 25609941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE.
    Saito T; Takeda A; Hashimoto K; Kobayashi A; Hayamizu T; Hagan GW
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2393-404. PubMed ID: 26604737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.
    Ohta K; Ichinose M; Tohda Y; Engel M; Moroni-Zentgraf P; Kunimitsu S; Sakamoto W; Adachi M
    PLoS One; 2015; 10(4):e0124109. PubMed ID: 25894430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
    van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
    Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids.
    Vogelberg C; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Hamelmann E; Engel M; Szefler S
    Respir Res; 2015 Feb; 16(1):20. PubMed ID: 25851298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.